LB Pharmaceuticals Inc (NASDAQ: LBRX) is a clinical-stage biopharmaceutical company developing drug candidates for FDA approval. The company generates no product revenue as of the 10-K filed 2026-03-26, with operations funded through equity and warrant issuances rather than commercial sales. Its lead product candidate is LB-102, which remains in clinical development pending regulatory approval. The company has disclosed it cannot determine when or whether it will generate revenue from commercialization of LB-102 or any future product candidates. Capital structure includes redeemable convertible preferred stock, multiple series of warrants (Class A, Class B, Series B, Series B-1, Pre-Funded), and common stock. The company relies entirely on third-party contract manufacturers and external clinical trial sites. LB Pharmaceuticals completed an IPO registration process in 2025, with its S-1 filed August 22, 2025, and has been audited by the same auditor since 2016.

Revenue model

No product revenue as of the 10-K filed 2026-03-26. The company is pre-revenue and funds operations through equity financing, including common stock and multiple warrant series.

Products and services

LB-102 is the lead product candidate, in clinical development and not yet approved by the FDA as of the 10-K filed 2026-03-26. No approved or commercialized products are disclosed in the filing excerpts.

Customers and end markets

No commercial customers as of the 10-K filed 2026-03-26. End market is pharmaceutical and psychiatric or neurological therapeutics, inferred from the clinical development context, though specific therapeutic area details are not supported by the excerpts provided.

Value-chain role

Clinical-stage drug developer reliant on third-party contract manufacturers for production and external clinical trial sites for patient enrollment and data generation. The company does not manufacture internally.

Geographic exposure

Primary regulatory focus is the FDA in the United States, with references to comparable foreign regulatory authorities. No specific non-U.S. revenue or operational geography is disclosed in the excerpts.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations